Clinical trials: Cancer of the Esophagus
Advanced MTAP-null Solid Tumors
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of Anvumetostat alone and in combination with…
- Trial name
- MTAPESTRY 101 (NCT05094336)
- Testing
- Anvumetostat, Docetaxel, Comparator Anvumetostat Test Tablet
- Where
- 75 sites in United States, Australia and 12 more
- Volunteers
- 329 people
- Sponsor
- Amgen
Barrett's Esophagus
WavSTAT® Optical Biopsy System to Target Esophageal Biopsies
The purpose of this study is to demonstrate the clinical utility of the WavSTAT Optical Biopsy System as an adjunctive tool to improve the endoscopist's clinical sensitivity to identify dysplasia or cancer in the esophagus.
- Trial name
- NCT00747136
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- SpectraScience
Esophageal Cancer
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
This is an open-label, multicenter, phase Ib study to evaluate the safety, tolerability, and preliminary efficacy of AN0025 in combination with chemoradiotherapy (CRT) in patients with locally advanced/locally recurrent…
- Trial name
- NCT05191667
- Testing
- AN0025
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
At present, concurrent chemoradiotherapy (cCRT) with platin-based dual-drug regimen is the standard treatment for inoperable, locally advanced esophageal cancer in patients with a good performance status.
- Conditions
- Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy, Concurrent Chemoradiotherapy
- Trial name
- NCT06342167
- Testing
- Radiotherapy, Programmed Cell Death Protein 1 Inhibitor, Immunonutrition support
- Where
- 10 sites in China
- Volunteers
- 57 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Neoplasms
Esophagectomy:Three-field Versus Two-field Lymphadenectomy (ECTOP-2002)
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-2002. Esophageal carcinoma is an aggressive disease with a poor prognosis.
- Trial name
- NCT01807936
- Testing
- Lymphadenectomy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Fudan University
Esophageal Cancer
Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer
The purpose of this clinical research study is to learn if BMS-181339 can shrink or slow the growth of the cancer in patients with advanced or recurrent esophageal cancer. The safety of this treatment will also be studied.
- Trial name
- NCT00344552
- Testing
- Paclitaxel
- Where
- 12 sites in Japan
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
Esophageal Cancer
Does Perioperative Goal Directed Therapy Using Flotrac Improve Outcomes in Esophagectomy Patients
The objective of this prospective, randomized controlled study is to ascertain whether the perioperative use of the FloTrac device to guide fluid and vasopressor management during esophagectomy improves patient outcomes.
- Trial name
- NCT02864355
- Testing
- Goal Directed Therapy
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Medical University of South Carolina
Esophageal Squamous Cell Carcinoma
HIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in Malawi
The primary purpose of this single-center, case-control, non-interventional study is to determine risk factors which contribute to the development of esophageal squamous cell carcinoma (ESCC) at Kamuzu Central Hospital (KCH) and…
- Trial name
- NCT03160209
- Where
- 2 sites in Malawi
- Volunteers
- 600 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Thoracic, Thoracic Neoplasm
A Prospective Study Frailty for Esophagectomy and Lung Resection in Thoracic Surgery
The purpose of this study is to develop an all-encompassing frailty model using laboratory and functional studies. A frailty model will help us determine prior to surgery who will require rehabilitation and skilled nursing needs…
- Conditions
- Thoracic, Thoracic Neoplasm, Lung Cancer, Esophageal Cancer
- Trial name
- NCT03413449
- Testing
- Frailty model
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- The Cleveland Clinic
Esophageal Cancer
dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy
This study is evaluating two treatment approaches for patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC) who have a good response to 2-3 cycles of induction chemoimmunotherapy.
- Trial name
- SORT (NCT07162506)
- Testing
- Surgery, Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Solid Tumor, Metastatic Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05267626
- Testing
- AU-007, Aldesleukin, Avelumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Aulos Bioscience, Inc.
Esophageal Cancer, Gastric Cancer
Fluorescence Image Guided Foregut Surgery
A high number of resected lymph nodes is an independent prognostic factor for improved survival after esophagectomy or gastrectomy for cancer.
- Trial name
- FOREGUT (NCT04734821)
- Testing
- Near Infra-Red Fluorescence Guided Surgery
- Where
- France
- Volunteers
- 60 people
- Sponsor
- IHU Strasbourg
Esophageal Carcinoma, Esophagogastric Junction Carcinoma
Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)
In this study participants with advanced/metastatic adenocarcinoma of the esophagus (EAC), squamous cell carcinoma of the esophagus (ESCC), or advanced/metastatic Siewert type I adenocarcinoma of the esophagogastric junction…
- Trial name
- NCT02559687
- Testing
- pembrolizumab
- Volunteers
- 121 people
- Sponsor
- Merck Sharp & Dohme LLC
Thoracic Solid Malignant Tumor
Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
To evaluate the safety and efficacy of Boron Neutron Capture Therapy (BNCT) in patients with recurrent thoracic solid tumors that are difficult to treat with standard radiation therapy or drug therapy and are unresectable.
- Trial name
- NCT06603987
- Testing
- BNCT, ［18F］FBPA
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Stella Pharma Corporation
Esophageal Cancer
Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with metastatic…
- Trial name
- NCT00003326
- Testing
- paclitaxel
- Where
- 30 sites in United States
- Volunteers
- 100 people
- Sponsor
- Theradex
Barrett Esophagus, Esophageal Neoplasm
ESD for the Treatment of Early Barrett's Neoplasia
This study assesses the quality of the resection of early neoplasia arinsing in Barrett's esophagus using endoscopic submucosal dissection.
- Trial name
- ESTEBAN (NCT02583087)
- Testing
- endoscopic submucosal dissection
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Hôpital Cochin
Breast Cancer, Colorectal Cancer
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody.
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT04244552
- Testing
- ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
- Where
- 19 sites in United States
- Volunteers
- 87 people
- Sponsor
- Atreca, Inc.
Siewert Type II Adenocarcinoma of Esophagogastric Junction
Siewert Type II Esophageal Adenocarcinoma: Relationship Between Histology and Survival
In Siewert type II adenocarcinoma, the relationship between adenocarcinoma sub types and survival, histologic/biologic patterns related to the presence/absence of gastric greater curvature metastases, were investigated.
- Trial name
- SiewertIIEAC (NCT03416101)
- Testing
- Total Gastrectomy
- Where
- 2 sites in Italy
- Volunteers
- 154 people
- Sponsor
- University of Bologna
Cancer Diagnosis, LungCancer
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
The goal of this observational study is to screen and differentiate common cancers in participants with or without suspicious lesions.
- Conditions
- Cancer Diagnosis, LungCancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT06036563
- Where
- 8 sites in China
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- Air Force Military Medical University, China
Esophageal Cancer
Oncolytic Virus in Esophageal Squamous Cell Carcinoma
This clinical trial is designed to evaluate the preliminary efficacy and safety of an oncolytic virus combined with chemotherapy and an immune checkpoint inhibitor in patients with initially unresectable, locally advanced…
- Trial name
- NCT07061704
- Testing
- Oncolytic Virus: Administered via intratumoral injection (metastatic lesions in the neck or supraclavicular lymph nodes) once every 3 weeks, for a total of two to four doses., Oncolytic Virus: Administered via intratumoral injection (primary lesions) once every 3 weeks, for a total of two to four doses.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.